ANNUAL REPORT
View an enhanced version of our Annual Report.
PROXY STATEMENT
View an enhanced version of our Proxy Statement.
The secure way to view our annual documents and vote your shares.
View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
Your vote is Important!
Please be sure to vote online now or by phone by dialing 844-209-9557.
June 14, 2022
9:30 AM Pacific Time
REGISTRATION DEADLINE:
June 10, 2022
5:00 PM Pacific Time
Note: You must register by the deadline to be eligible to participate in the meeting.
ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
